With the current cisplatin and carboplatin shortages, for HPV+ H&N patients with indications for concurrent chemoRT, which agent do you recommend next?

The question of 2nd line therapy is difficult due to the dearth of data.

This leaves essentially 3 choices - immunotherapy, cetuximab, or other cytotoxic agents.

Regarding immunotherapy, recent trials for concurrent IO have been mixed, tending to compare IO vs Cetux. The main take-home though, is the...

Altered fractionation, preferably hyper fractionation, and a taxane. If hyper fractionation is not an option, 6-week SIB.

I assume the question is what to use for first line where platinum (cisplatin or carbo/taxol) is indicated for concurrent therapy but unable to access cisplatin or carboplatin due to the national shortage. Unfortunately, this is a real and increasing problem.

If that is the case, I would consider doc...